Background
==========

DNA methylation at the C5 position of a cytosine within a CpG dinucleotide is a primary mechanism in gene silencing \[[@B1]\]. Approximately 60% to 90% of the CpG dinucleotides in the genome of a vertebrate are methylated \[[@B2],[@B3]\]. 5-aza-2-deoxycytidine (5-aza-dC) exerts its demethylating function by sequestering DNA methyltransferase 1 (DNMT1) to 5-aza-dC-substituted DNA via the irreversible binding of the cysteine in the catalytic domain of DNMT1 to the 6 position of the cytidine ring (4,5). This decreases the cellular concentration of DNMT1, which leads to genomic DNA demethylation in the course of successive cell divisions \[[@B6]-[@B8]\]. 5-aza-dC has been shown to reactivate silenced genes *in vitro*\[[@B9],[@B10]\].

Regulation of gene expression in eukaryotes also involves the acetylation and deacetylation of histones, followed by chromatin remodeling \[[@B11]-[@B14]\]. Histones H3 and H4 are acetylated on the ε-amino groups of lysines to a greater extent than H2A or H2B \[[@B15]\]. Histone acetylation increases the accessibility of nucleosomal DNA to transcription factors and other regulatory molecules \[[@B16],[@B17]\]. Turnover of the acetyl groups on histone molecules occurs very rapidly in cells \[[@B18],[@B19]\] and the level of acetylation is controlled by an equilibrium of histone acetyltransferase and histone deacetylase (HDAC) activities \[[@B20]-[@B23]\]. Trichostatin A (TSA) is a reversible inhibitor of HDAC *in vitro*and *in vivo*, active at nanomolar concentrations, that causes a marked increase in histone acetylation \[[@B24]\].

DNA methylation and histone deacetylation can be mechanistically linked in gene silencing \[[@B25]\]. For example, the silenced rRNA genes can be re-expressed after either 5-aza-dC or TSA treatments \[[@B26]-[@B29]\] but treatment with both drugs together does not result in additional re-expression, suggesting that DNA methylation and histone deacetylation cooperate to silence rRNA gene expression \[[@B26]\]. Microarray analyses using human colorectal cancer cells showed that HDAC inhibitors alone could re-express some genes, but not genes that contain hypermethylated CpG islands; genes with hypermethylated CpG islands were only re-expressed after 5-aza-dC treatment \[[@B30]\]. 5-aza-dC and TSA have been shown to act in a synergistic fashion to re-express silenced genes in colorectal carcinoma cells \[[@B31],[@B32]\].

The human hepatocellular carcinoma cell line HepG2 \[[@B33]\] synthesizes and secretes many of the major human plasma proteins, such as fibrinogen, plasminogen, and α2-macroglobulin \[[@B34]\]. These cells exhibit many cellular features of normal human hepatocytes \[[@B35]\] but also display characteristics resembling those of a fetal hepatocyte, because albumin and α-fetoprotein are both expressed; adult hepatocytes exclusively express albumin \[[@B36]\]. HepG2 cells also fail to express many of the hepatocyte-specific metabolic enzymes that characterize the neonatal and adult liver \[[@B34],[@B37]\]. These cells express very low levels of the alcohol dehydrogenase 1B (*ADH1B*) and *ADH1C*genes, both of which are regulated by epigenetic mechanisms in HepG2 cells \[[@B38]\].

We were interested in determining what genes are regulated by DNA methylation and histone deacetylation in HepG2 cells. Affymetrix^®^HG-U133 Plus 2.0 microarrays were used to measure the expression of approximately 54,000 transcripts in the presence and absence of 5-aza-dC and/or TSA. We report that the expression of many genes was altered upon 5-aza-dC treatment, and many fewer with TSA treatment. Groups of genes involved in xenobiotic metabolism, steroid biosynthesis, and CCAAT element binding were affected by 5-aza-dC (some exclusively with 5-aza-dC and TSA). Most of these genes are also expressed in the fetal and adult liver.

Results
=======

Global gene expression in treated HepG2 cells
---------------------------------------------

We treated HepG2 cells with 5-aza-dC to inhibit DNA methylation, TSA to inhibit histone deacetylation, or the combination of both 5-aza-dC and TSA, and measured changes in gene expression using Affymetrix^®^HG-U133 Plus 2.0 microarrays. To ensure that 5-aza-dC treatments resulted in DNA demethylation, we performed methylation-sensitive PCR on a site 2916 bp upstream of the *ADH1B*translational start site. If the site is methylated, it is resistant to *Hpa II*digestion and can be amplified by PCR; if it is demethylated, this site will be cleaved and can no longer be amplified. Figure [1A](#F1){ref-type="fig"} demonstrates that genomic DNA from untreated cells was methylated at the bp -2916 *Hpa II*site, as demonstrated by the presence of robust 319 bp PCR products. DNAs from 5-aza-dC-treated HepG2 cells had methylation levels less than one-fifth that of untreated cells, as evidenced by the absence of PCR products (Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}).

Many genes were affected by the treatment of 5-aza-dC and/or TSA in HepG2 cells (Table [1](#T1){ref-type="table"}). The expression of 1504 probe sets was changed by 5-aza-dC (p-value of 0.01; FDR ≤ 0.17), 535 by TSA (FDR ≤ 0.46), and 1929 by the combination of 5-aza-dC and TSA (FDR ≤ 0.13) (Table [1](#T1){ref-type="table"}). Hierarchical clustering of the microarrays based on a set of 355 genes that varied most across the experiment (chosen based upon the ratio of standard deviation to the mean ≥ 0.6, without regard for whether the variation was within or between conditions) showed a clear separation of cells that received 5-aza-dC from cells that did not (Figure [2](#F2){ref-type="fig"}). Within this major division, cells treated with TSA did not segregate from untreated cells. Thus, 5-aza-dC had a marked effect on gene expression while TSA had only a minimal effect. At a p-value of 0.01, 5-aza-dC treatment increased the expression of 883 probe sets while decreasing the expression of 620 probe sets. TSA increased 244 and decreased 291 while 5-aza-dC plus TSA increased 1078 and decreased 851. [Additional file 1](#S1){ref-type="supplementary-material"} shows genes for which any of the treatments significantly altered its expression (p ≤ 0.05).

Gene re-expression in 5-aza-dC treated cells
--------------------------------------------

DNA methylation is known to play a large role in silencing the expression of many genes, thus we wanted to examine which genes in HepG2 cells were re-expressed by treatment with 5-aza-dC. We defined re-expressed stringently, requiring that the gene be undetectable (\"Absent\" as defined by the Affymetrix MAS5 algorithm) on any of the 4 arrays before treatment and detected (\"Present\") on all 4 arrays after treatment \[see [Additional file 2](#S2){ref-type="supplementary-material"}\]. Treatment of HepG2 cells with 5-aza-dC restored the expression of 211 probe sets (188 different genes). Only two genes were turned off by 5-aza-dC. The additional presence of TSA did not substantially change the number of probe sets (208) that were re-expressed. A relaxed definition of re-expression (allowing one of the 8 arrays in the comparison to be called \"Marginal\") resulted in an additional 45 probe sets being re-expressed by 5-aza-dC and 33 by 5-aza-dC and TSA. Several genes regulated by imprinting were re-expressed or significantly up-regulated (*H19*) by treatment with 5-aza-dC, including *H19*(maternally expressed), *NDN*(paternal), *NNAT*(paternal), and *MEG3*(maternal) \[see [Additional file 2](#S2){ref-type="supplementary-material"}\]. The latter three genes were not detectably expressed in untreated cells; *H19*was minimally detected in untreated cells but is clearly being re-expressed. Another set of re-expressed genes included *TSPY1*, *DAZ2*, and *DAZ4*; these genes are involved in spermatogenesis \[see [Additional file 2](#S2){ref-type="supplementary-material"}\].

Tissue culture and cancer cells are known to have an increase in genome wide methylation of CpG islands \[[@B39]-[@B42]\]. Thus, we examined the frequency of CpG islands within the promoters of 18 (10%, randomly selected) of the genes re-expressed by 5-aza-dC. Using CpG Island Finder \[[@B43],[@B44]\] we found that 13 of 18 genes contained at least one CpG island. Of the 10 genes whose expression was confirmed by quantitative real-time RT-PCR (below) we found that 8 contained at least one CpG island.

Only four genes were turned on by the combination of 5-aza-dC plus TSA but remained off after treatment with 5-aza-dC or TSA alone (Table [2](#T2){ref-type="table"}). The most striking of these was chromogranin A (*CHGA*), which is a central regulator of catecholamine storage and release \[[@B45]\]; expression was not detected on any of the arrays for 5-aza-dC, TSA, or untreated cells but it was present on all 4 arrays from 5-aza-dC plus TSA-treated cells. We confirmed this synergism by quantitative real-time RT-PCR. The expression of *CHGA*was not reliably detected in untreated cells or in two samples of TSA-treated cells. Expression was detected at very low-levels in two other TSA-treated samples and in all three 5-aza-dC-treated cells (*CHGA*C~t~- *GAPDH*C~t~\[ddC~t~\] = 7.7, corresponding to 0.5% of the level of *GAPDH*). Cells treated with the combination of both 5-aza-dC and TSA showed greatly enhanced expression of *CHGA*, approximately 80-fold, illustrating the synergy (ddC~t~= 1.4; 38% of the level of *GAPDH*).

Groups of genes involved in liver processes are affected by 5-aza-dC
--------------------------------------------------------------------

Genes affected by 5-aza-dC treatment were further analyzed to determine whether the expression of particular groups of genes (as defined by Gene Ontology) was affected by DNA methylation. We were initially interested in identifying groups of genes related to liver processes since this cell line is of liver origin (hepatoma). Table [3](#T3){ref-type="table"} shows groups of genes involved in xenobiotic metabolism, steroid biosynthesis, and CCAAT element binding that are regulated by DNA methylation; some genes are regulated by both DNA methylation and histone deacetylation, but not solely methylation. Many genes within these groups are also expressed in the developing fetal liver and adult liver (Table [3](#T3){ref-type="table"}).

Verification of microarray results by quantitative real-time RT-PCR
-------------------------------------------------------------------

Quantitative real-time RT-PCR assays were performed to confirm microarray gene expression changes (Table [4](#T4){ref-type="table"}). Genes were selected based on their role in the liver, imprinting status, cell cycle function, or as important transcription factors. The pattern of differences detected by RT-PCR was consistent with those from the microarrays, but the fold-changes obtained by real-time RT-PCR assays were, in most cases, much greater than fold-changes seen in microarray analyses. This observation was particularly true for genes re-expressed by 5-aza-dC treatment; in that case, the denominator in the microarray experiment (baseline, control value) is essentially zero (the gene is called \"Absent\") so the exact fold change calculated from microarray data is not meaningful or accurate. RT-PCR assays allow one to obtain a lower baseline value, and therefore a higher fold-change. It should be noted that we have not determined the amplification efficiency of each assay so these calculated fold-changes are based on 100% efficiency; this can overstate the fold change.

Discussion
==========

DNA methylation has a larger role in the inhibition of gene expression in the human hepatoma cell line HepG2 than does histone deacetylation. This is demonstrated by the greater effect by the DNMT inhibitor 5-aza-dC on gene expression than of the HDAC inhibitor TSA, as evidenced by the numbers of probe sets with altered gene expression (Table [1](#T1){ref-type="table"}). It is also demonstrated by hierarchical clustering (Figure [2](#F2){ref-type="fig"}) in which the cells treated with 5-aza-dC, either alone or with TSA, segregated from cells not treated with TSA. 5-aza-dC treatment re-expressed 211 probe sets (188 genes) that had been silent in HepG2 cells \[see [Additional file 2](#S2){ref-type="supplementary-material"}\], and up regulated more genes than were down regulated. In the overall pattern of gene expression, we do not detect much synergy between 5-aza-dC and TSA on gene expression in these cells. A small number of genes (4) required both 5-aza-dC and TSA for re-expression; we confirmed the synergistic effects of 5-aza-dC and TSA on *CHGA*gene expression by performing quantitative real-time RT-PCR.

A subset of autosomal genes, known as imprinted genes, display expression exclusively from one of the parental alleles \[[@B46]\]. The imprinted genes *NDN*, *NNAT*, and *MEG3*were turned on in 5-aza-dC-treated cells (Table [4](#T4){ref-type="table"} and see [Additional file 2](#S2){ref-type="supplementary-material"}), demonstrating that the DNA demethylation was sufficient to re-express genes silenced by DNA methylation in the HepG2 cells. The expression of *H19*(maternal) was greatly increased (156-fold \[see [Additional file 2](#S2){ref-type="supplementary-material"}\]; essentially turned on) while the expression of *IGF2*(paternal) was decreased (-4.2-fold, p = 0.02 \[see [Additional file 1](#S1){ref-type="supplementary-material"}\]. Both genes lie together on chromosome 11p15, and the upstream region of *H19*is the downstream region of *IGF2*; this intergenic region, also known as the differentially methylated region, is responsible for monoallelic expression of both genes \[[@B47]-[@B49]\]. If this DMR is unmethylated, the transcription factor CTCF can bind and block the activity of an enhancer that activates *IGF2*expression; this allows the enhancer to now interact with the *H19*promoter \[[@B47]\]. Our results are consistent with this.

5-aza-dC also turned on the expression of several Y chromosome-specific genes \[see [Additional file 2](#S2){ref-type="supplementary-material"}\]. Past studies using prostate cancer cell lines showed that DNA methylation regulates the expression of these genes and that 5-aza-dC can restore their expression \[[@B50]\]. The expression of *TSPY1*is normally restricted to the testis where it plays a role in spermatogonial proliferation \[[@B51]\]. *TSPY1*contains a putative CpG island in its promoter that is hypermethylated in melanoma cell lines; treatment with 5-aza-dC can restore *TSPY1*expression \[[@B52]\]. The *DAZ*cluster of genes are thought to be involved in germ cell differentiation in humans and old world monkeys \[[@B53]\]; deletions in this region can cause infertility in males \[[@B54]\]. This finding is interesting given that we treated hepatoma cells, a cell type that normally does not express spermatogenesis genes. It confirms that DNA methylation plays a large role in shutting down the expression of many genes that have no role in contributing to the proper functioning of that cell type.

We further analyzed genes that were significantly affected by 5-aza-dC treatment and identified groups of genes that are involved in xenobiotic metabolism, steroid biosynthesis, and CCAAT element binding (Table [3](#T3){ref-type="table"}). The most affected in the xenobiotic metabolism group, the *CYP3A*genes, play major roles in metabolic disposition of wide variety of drugs \[[@B55]\]. *CYP3A4*and *CYP3A5*comprise nearly 30%-40% of total hepatic cytochrome p450 \[[@B55]\] while *CYP3A7*expression is restricted to the fetal liver \[[@B56]\]. *CYP3A*expression in untreated HepG2 cells is fairly low (signals ranging from 370 to 968), suggesting that their expression is reduced in these partially de-differentiated cells; however, 5-aza-dC greatly increased the expression of each *CYP3A*gene. This increase in expression was confirmed by real-time RT-PCR for *CYP3A7*(Table [4](#T4){ref-type="table"}).

Genes within the steroid biosynthesis group also included two *CYP*genes. The *CYP19A1*gene, which was re-expressed by 5-aza-dC treatment \[see [Additional file 2](#S2){ref-type="supplementary-material"}\], encodes the main estrogen biosynthesis enzyme, which converts androgen to estrogen \[[@B57]\]. *CYP19A1*expression can be increased in endometriotic stromal cells upon *in vivo*down-regulation of C/EBPβ \[[@B58]\]. This finding is interesting given that C/EBPβ expression was decreased by 2-fold; this may contribute to *CYP19A1*re-expression. The CYP17A1 enzyme (Table [3](#T3){ref-type="table"}) functions in the biosynthesis of testosterone through the regulation of 17-hydroxylase and 17, 20-lyase \[[@B59]\]. CYP17A1 is not expressed in the fetal or adult liver; hence DNA methylation may be a major mechanism to transcriptionally silence its expression in the liver.

We examined seven genes that bind CCAAT DNA elements to regulate transcription of many important liver genes (Table [3](#T3){ref-type="table"}). Most notable are the three genes encoding C/EBPα, C/EBPβ and C/EBPγ (Table [3](#T3){ref-type="table"}; *CEBPA*, *CEBPB*, and *CEBPG*) that were differentially affected by 5-aza-dC or TSA and the combination of 5-aza-dC and TSA. Surprisingly, the expression of *CEBPB*and *CEBPG*were decreased by 5-aza-dC; because methylation generally inhibits gene expression \[[@B1]\], this down-regulation could be a secondary effect of the increase in an inhibitory factor. *CEBPA*was up-regulated by TSA and the combination of 5-aza-dC and TSA, but not with 5-aza-dC alone. The transcriptional state of many other hepatocyte-specific genes in these cells is likely altered based on the expression profile of these C/EBP genes. *CEBPB*can generate two isoforms from a single mRNA: the full-length protein termed liver activation protein (LAP) or the truncated liver inhibitory protein (LIP) isoform \[[@B60]-[@B63]\]. LIP is a dominant-negative factor that can attenuate transcription by forming a heterodimer with LAP to negate the transactivation ability of LAP \[[@B62]\]. LIP is still able to attenuate the transcriptional activity of LAP even when present at sub-stoichiometric amounts (i.e. LAP/LIP ratio of 5:1) \[[@B62],[@B64]\]. C/EBPγ heterodimerization with C/EBPα and LAP can also attenuate transcription of C/EBP responsive promoters, suggesting dominant negative regulation by this factor \[[@B65]\]. Hence, the decreased expression of C/EBPβ and C/EBPγ transcripts may aid in increasing the expression of the hepatocyte-specific genes they regulate.

The *CEBPA*gene is regulated by histone deacetylation (and slightly increased with 5-aza-dC and TSA) in the HepG2 human hepatoma cell line. An increase in *C*/EBPα expression will increase the expression of several hepatocyte-specific genes that are regulated by this factor. However, a larger picture emerges from our data. HepG2 cells display many characteristics of fetal and adult hepatocytes. Many genes regulated by DNA methylation that function in liver processes (Table [3](#T3){ref-type="table"}) are expressed in the fetal and adult liver. DNA demethylation may be, in part, responsible for silencing the expression of fetal liver genes. C/EBPα and C/EBPβ may play important roles in this. The haptoglobin (Hp) gene, which is important in liver development, is transcriptionally regulated by C/EBPα and C/EBPβ in the rat liver; Dinic *et al*. have shown that Hp transcription is regulated by C/EBPα during normal liver development while C/EBPβ regulates this gene during the acute phase response during the later phase of differentiation and in the adult \[[@B66]\]. Also, the suppression of *C/EBPα*expression may be a prerequisite to biliary cell differentiation in a hepatoblast population in the developing mouse liver \[[@B67]\].

Conclusion
==========

In summary, we demonstrate that DNA methylation plays a much larger role than histone deacetylation in regulating gene expression in HepG2 human hepatoma cells. Many genes were in fact turned on in these cells by the DNMT inhibitor 5-aza-dC; which included imprinted genes and spermatogenesis genes. 5-aza-dC affected groups of genes involved in liver processes such as xenobiotic metabolism, steroid biosynthesis, and CCAAT element binding. A majority of the genes in these groups are expressed in the developing fetal and adult liver indicating that DNA methylation may play a role in restricting the expression of fetal liver genes and in shutting down expression in hepatoma cells.

Methods
=======

Drug treatments
---------------

5-aza-dC (Sigma, St. Louis, MO) and TSA (Sigma) were prepared in dimethyl sulfoxide (DMSO) (Sigma). HepG2 cells (HB-8065; ATCC, Manassas, VA) (5 × 10^5^cells) were plated on 100 mm culture dishes and grown in minimum essential medium (Sigma) with 10% fetal bovine serum (Life Technologies, Rockville, MD) and 2 mM glutamine in a 5% CO~2~atmosphere. A 2 × 2 experimental design was used: cells were treated with 2.5 μM 5-aza-dC, 500 nM TSA, both 2.5 μM 5-aza-dC and 500 nM TSA, or DMSO (untreated). Plates were seeded and harvested at the same time; appropriate dishes were treated with 5-aza-dC 48 h after cell seeding and their media and drugs were replaced every 24 h. TSA was incubated with appropriate dishes for the last 24 h before harvesting. DNA and RNA were extracted 4 days after the initial 5-aza-dC treatment using TRIzol^®^(Invitrogen, Carlsbad, CA).

DNA methylation analysis
------------------------

Methylation-sensitive PCR was modified from a protocol \[[@B68]\] and quantitation of PCR products were previously described by Dannenberg *et al*. \[[@B38]\]. This assay is based on the fact that *Hpa II*cannot digest a methylated CCGG site; thus fragments containing methylated CCGG sites remain intact and can be amplified by PCR, whereas unmethylated CCGG sites are cut and cannot be amplified. The region upstream of *ADH1B*from bp -2956 to -2638 was analyzed using primers HE1741/1742 (Table [5](#T5){ref-type="table"}).

Microarray analysis
-------------------

Total RNA prepared from HepG2 cells was treated with 1 U of DNase I, RNase-Free (Roche, Indianapolis, IN) per microgram of RNA. An RNeasy^®^Mini Kit (Qiagen, Valencia, CA) was used to purify RNA. RNA quality was then tested using a Bioanalyzer (Agilent Technologies, Palo Alto, CA) and by measuring absorbance from 210 to 350 nm. RNA preparations from four independent dishes from each experimental condition (5-aza-dC, TSA, both 5-aza-dC and TSA, and untreated) were separately processed and analyzed. Ten micrograms of total RNA was synthesized into cDNA for each sample, and then biotinylated cRNA was generated by *in vitro*transcription, following the standard Affymetrix protocols \[[@B69]\]. Biotinylated cRNAs were fragmented, and each sample was hybridized to an Affymetrix^®^HG-U133 Plus 2.0 gene chip (54,675 probe sets) at 42°C for 17 h. Chips were washed, stained, and scanned following the standard Affymetrix protocol \[[@B69]\].

Statistical analysis
--------------------

Expression data generated by the Affymetrix Microarray Suite^®^, version 5.0, were exported and analyzed using Microarray Data Portal (MDP) \[[@B70]\]. Data have been deposited into GEO \[[@B71]\] under Series accession number GSE5230. Probe sets that were not called present on at least 50% of the arrays in at least one-treatment group were eliminated before further analysis; these primarily represent noise \[[@B72],[@B73]\]. Log-transformed signals were then compared using Welch\'s approximate *t*-test, which allows for unequal variance. False discovery rate (FDR) was calculated according to Benjamini and Hochberg \[[@B74]\]. Genes were considered turned from \"off to on\" or \"on to off\" if the difference of the fraction present was +/- 1; that is, if genes went from \"Absent\" (according to the MAS5 algorithm) in all 4 arrays to \"Present\" in all four arrays, or *vice versa*and the log signal differed significantly (p ≤ 0.05). Genes turned on by the combination of 5-aza-dC plus TSA (as defined above) but not by 5-aza-dC alone were also selected, based on a p value for both vs. 5-aza-dC \<0.05 and difference in fraction present ≥ 0.5. Gene groupings were created using Gene Ontology on MDP; the CCAAT-binding protein genes were grouped manually. Fetal liver expression was determined by using the Expression Profile Viewer (NCBI). Genes are considered as expressed in the fetal liver if they are expressed in the liver and also expressed in the embryo.

Putative CpG islands were identified using the CpG Island Finder \[[@B43],[@B44]\]. We selected a random 10% of the genes that were re-expressed \[see [Additional file 2](#S2){ref-type="supplementary-material"}\] and examined their promoters from -1500 to +500 bp. We also examined 10 genes that were confirmed by RT-PCR (Table [4](#T4){ref-type="table"}). CpG Island Finder uses a sliding window 201 bp in length to calculate the CpG dinucleotide percentage for each window where it defines the maximum of these CpG percentages as the CpG score and the corresponding window as the CpG window \[[@B43]\]. Assuming a bimodal normal distribution and an overlap of 10% (5% from each group), 6.5 as a cutoff value is often used because it satisfies the condition μ+2σ \< 6.5 \< μ-2σ \[[@B43]\]. However, we used the default value of 6%, set by the CpG Island Finder \[[@B44]\], to identify promoter CpG islands.

Hierarchical clustering
-----------------------

A set of 355 genes that varied across the experiment (without consideration of whether variation was within or between conditions, to avoid bias) was selected based upon a coefficient of variation (CV; ratio of standard deviation to mean) of 0.6 or greater. Hierarchical clustering of the microarrays \[[@B75]\] was performed using MDP.

Real-time quantitative RT-PCR
-----------------------------

The following human mRNA sequences: *CDK10, CEBPA, CEBPB, CHGA, CYP3A7, GSTP1, H19, NNAT, PKIB, S100A4*, and *TSPY1*were used to design gene-specific primers for real-time RT-PCR using MacVector (Accelrys, San Diego, CA). Primer sequences were tested for uniqueness by aligning them against the human genome using NCBI BLAST \[[@B76]\]. The RT-PCR products and Accession numbers (GenBank) for each mRNA sequence are listed in Table [6](#T6){ref-type="table"}; the sequences of the primers used are listed in Table [5](#T5){ref-type="table"}.

Four 500 ng aliquots of TSA-treated and untreated RNA preparations used in the microarray analyses and three 500 ng aliquots of 5-aza-dC-treated and 5-aza-dC and TSA-treated (only three used for these conditions due to little or no total RNA available after microarray analyses) were reverse transcribed using the SuperScript First Strand Synthesis System (Invitrogen). Resulting cDNAs were diluted 1:25, then amplified using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). *GAPDH*(glyceraldehyde-3-phosphate dehydrogenase) expression was quantified using TaqMan^®^GAPDH Control Reagents (Applied Biosystems) as an internal control to normalize each gene against (note: *GAPDH*amplification not run in parallel with each gene due to limiting amounts of cDNA). PCR products were quantified in real-time using an ABI PRISM^®^7700 Sequence Detection System (Applied Biosystems). PCR conditions were 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 sec and 51--60°C for 20 sec. C~t~values for each gene and condition were normalized against *GAPDH*and then each condition was normalized against the untreated cells to obtain a fold-change. Welch\'s *t*-tests were performed to analyze the real-time RT-PCR data. We did not determine the amplification efficiency of each assay; the fold-changes are calculated based on 100% efficiency.
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###### Additional File 1

**Genes that differed between untreated and treated cells**. Genes that were present in at least half of the arrays in at least one group, and that significantly differ (p ≤ 0.05) between untreated cells and any of the treatments (5-aza-dC, TSA, or both 5-aza-dC and TSA). Genes are sorted in the order: gene name, Unigene number, and condition; genes lacking gene symbols are sorted in order of Unigene number.

###### 

Click here for file

###### Additional File 2

**Probe sets re-expressed by 5-aza-dC**. Probe sets that were re-expressed by 5-aza-dC treatment are shown (see Methods for details).

###### 

Click here for file
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Figures and Tables
==================

![**Treatment of HepG2 cells with 2.5 μM 5-aza-dC results in DNA demethylation**. Demethylated DNA is cleaved by *Hpa II*digestion and cannot be amplified; therefore the amount of methylated DNA is reflected in the amount of PCR product. (A) Electropherogram of genomic DNA from untreated HepG2 cells or cells treated with 5-aza-dC; DNA was extracted and digested with *Rsa I*+ *Hpa II*and subjected to PCR using primers that flank the endogenously methylated *Hpa II*site at bp -2916 upstream of the *ADH1B*gene. (B) Quantitation of the PCR products produced in (A) using 2 X PicoGreen^®^and an ABI PRISM^®^7700 Sequence Detection System. The order of the quantitation is the same as the order of the PCR products seen in (A).](1471-2164-7-181-1){#F1}

![**Hierarchical cluster analysis of genes that vary across the experiment**. Genes that varied across the experiment (CV ≥ 0.6) were selected and clustered \[75\] based upon Euclidean distance. Colors represent differences from the median expression of the gene across different conditions: the top 5% are yellow, then in declining order from red to green (median), then progressively more blue (below median) to blue (bottom 5%).](1471-2164-7-181-2){#F2}

###### 

Number of probe sets changed by different treatments

  **p-/values**^**1**^   **5-aza-dC**     **TSA**       **5-aza-dC and TSA**
  ---------------------- ---------------- ------------- ----------------------
  **0.05**               3974 (.326)^2^   2161 (.569)   4927 (.257)
  **0.01**               1504 (.172)      535 (.460)    1929 (.132)
  **0.001**              346 (.075)       55 (.455)     468 (.053)
  **0.0001**             73 (.041)        10 (.200)     126 (.024)

^1^Based on Welch\'s *t*-test log(signal).

^2^Number and (FDR) of probe sets significant at each p-value.

###### 

Genes re-expressed by 5-aza-dC and TSA, but not by either drug alone

  Gene Symbol   Unigene     Affymetrix ID   Fold Change   p-value   Control Signal   5-aza-dC + TSA Signal   5-aza-dC Signal   Description
  ------------- ----------- --------------- ------------- --------- ---------------- ----------------------- ----------------- --------------------------------------------------
  CHGA          Hs.150793   204697_s\_at    3.03          0.012     214              648                     214               Chromogranin A (parathyroid secretory protein 1)
  TKTL1         Hs.102866   214183_s\_at    57.92         0.00004   49               2809                    1276              Transketolase-like 1
  BG1           Hs.250616   206465_at       6.16          0.00007   172              1057                    630               Lipidosin
  \-            Hs.399852   1559213_at      43.98         0.0003    19               842                     193               IMAGE:5394246, mRNA

###### 

Groups of genes involved in liver processes that are affected by 5-aza-dC.

  ------------------------------------ ------------- ------------------- ----------------- ------------- --------- -------------------- --------------------- ------------------------------------------------------------------------------------------------------
  **Gene Symbol**                      **Unigene**   **Affymetrix ID**   **Fold Change**   **p-value**   **FDR**   **Control Signal**   **5-aza-dC Signal**   **Description**
  **Xenobiotic Metabolism**                                                                                                                                   
  ABHD6\^                              Hs.476454     221552_at           1.82              0.00394       0.12238   634                  1151                  Abhydrolase domain containing 6
  AKR1C1\^                             Hs.460260     1555854_at          2.92              0.00027       0.04452   345                  1007                  Aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-a
  CYP3A4\^                             Hs.442527     205999_x\_at        1.78              0.01792       0.21785   370                  660                   Cytochrome P450, family 3, subfamily A, polypeptide 4
  CYP3A5\^                             Hs.150276     214234_s\_at        2.53              0.00159       0.08806   968                  2447                  Cytochrome P450, family 3, subfamily A, polypeptide 5
  CYP3A7\^                             Hs.111944     211843_x\_at        4.11              0.00387       0.12175   515                  2120                  Cytochrome P450, family 3, subfamily A, polypeptide 7
  HAMP\^                               Hs.8821       220491_at           2.34              0.01066       0.17693   1076                 2512                  Hepcidin antimicrobial peptide
  UGT1A6\^                             Hs.546397     215125_s\_at        2.73              0.00318       0.11285   143                  389                   UDP glycosyltransferase 1 family, polypeptide A9
  UGT2B15\^                            Hs.150207     207392_x\_at        1.79              0.01965       0.22477   323                  577                   UDP glycosyltransferase 2 family, polypeptide B15
  UGT2B28                              Hs.137585     211682_x\_at        -2.69             0.00131       0.08111   11036                4109                  UDP glycosyltransferase 2 family, polypeptide B28
  **Steroid Biosynthesis**                                                                                                                                    
  CYP17A1                              Hs.438016     205502_at           1.92              0.00208       0.09647   325                  622                   Cytochrome P450, family 17, subfamily A, polypeptide 1
  CYP19A1\^                            Hs.511367     203475_at           2.43              0.00356       0.11831   470                  1144                  Cytochrome P450, family 19, subfamily A, polypeptide 1
  CYP51A1\^                            Hs.417077     202314_at           -1.31             0.00975       0.17073   11672                8910                  Cytochrome P450, family 51, subfamily A, polypeptide 1
  DHCR7\^                              Hs.503134     201791_s\_at        -1.4              0.02202       0.23665   3628                 2588                  7-dehydrocholesterol reductase
  FDFT1\^                              Hs.546253     208647_at           -1.37             0.00820       0.16076   24377                17858                 Farnesyl-diphosphate farnesyltransferase 1
  FDXR\^                               Hs.69745      207813_s\_at        2.31              0.00046       0.05618   2066                 4764                  Ferredoxin reductase
  HMGCR\^                              Hs.11899      202539_s\_at        -1.34             0.03567       0.28427   10570                7864                  3-hydroxy-3-methylglutaryl-Coenzyme A reductase
  HSD17B1\^                            Hs.500159     205829_at           6.02              0.00853       0.16330   157                  944                   Hydroxysteroid (17-beta) dehydrogenase 1
  HSD17B2\^                            Hs.162795     204818_at           2.68              0.00198       0.09502   1818                 4869                  Hydroxysteroid (17-beta) dehydrogenase 2
  LSS\^                                Hs.517366     202245_at           -1.32             0.00717       0.15151   5751                 4356                  Lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)
  PMVK                                 Hs.30954      203515_s\_at        1.6               0.00661       0.14527   1046                 1674                  Phosphomevalonate kinase
  RODH\^                               Hs.524513     37512_at            3.67              0.00046       0.05648   173                  634                   3-hydroxysteroid epimerase
  SC5DL\^                              Hs.287749     211423_s\_at        -1.19             0.01127       0.18081   10122                8494                  Sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, fungal)-like
  SQLE\^                               Hs.71465      209218_at           -1.32             0.00603       0.14008   16131                12229                 Squalene epoxidase
  STARD4\^                             Hs.93842      226390_at           -1.22             0.01833       0.21953   4385                 3593                  START domain containing 4, sterol regulated
                                                                                                                                                              
  **CCAAT element binding proteins**                                                                                                                          
  CEBPA\*\^                            Hs.76171      204039_at           1.69              0.00049       0.04052   3106                 5262                  CCAAT/enhancer binding protein (C/EBP), alpha
  CEBPB\^                              Hs.517106     212501_at           -1.95             0.01864       0.22082   28789                14762                 CCAAT/enhancer binding protein (C/EBP), beta
  CEBPG\^                              Hs.429666     225527_at           -2.15             0.04308       0.30614   3734                 1741                  CCAAT/enhancer binding protein (C/EBP), gamma
  CEBPZ\*\^                            Hs.135406     203341_at           -1.34             0.00286       0.08197   4880                 3655                  CCAAT/enhancer binding protein zeta
  CUTL1\*\^                            Hs.438974     214743_at           -1.57             0.00957       0.1289    1672                 1067                  Cut-like 1, CCAAT displacement protein (Drosophila)
  NFIC\*\^                             Hs.170131     226895_at           1.23              0.01727       0.16248   1452                 1786                  Nuclear factor I/C (CCAAT-binding transcription factor)
  NFYC\^                               Hs.233458     202215_s\_at        1.38              0.01163       0.18301   1612                 2228                  Nuclear transcription factor Y, gamma
  ------------------------------------ ------------- ------------------- ----------------- ------------- --------- -------------------- --------------------- ------------------------------------------------------------------------------------------------------

\* = Genes that are only significantly affected by both 5-aza-dC and TSA.

\^ = Expressed in fetal and/or adult liver.

###### 

Validation of fold-changes from microarray analyses by real-time RT-PCR

                                  **5-aza-dC**   **TSA**          **5-aza-dC and TSA**                                 
  --------------------- --------- -------------- ---------------- ---------------------- -------------- -------------- -----------------
  ***CDK10***^**3**^    300\*     3.5 (.00013)   8.3 (.00000)     NT^2^                  NT             3.8 (.00001)   7.2 (.00000)
  ***CEBPA***^**3**^    3106      NT             NT               1.43 (.0038)           4.16 (.004)    1.7 (.00049)   10.4 (.00000)
  ***CEBPB***^**3**^    28789     -2.0 (.019)    -2.6 (.0008)     NT                     NT             -2.0 (.019)    -3.5 (.00009)
  ***CYP3A7***^**3**^   515\*     4.0 (.0043)    11 (.00000)      NT                     NT             4.3 (.0043)    8.0 (.00000)
  ***GSTP1***^**3**^    367\*\*   8.5 (.00014)   18200 (.00000)   NT                     NT             12 (.00005)    107000 (.00000)
  ***H19***^**3**^      255       156 (.00000)   5080 (.00000)    NT                     NT             141 (.00000)   330 (.00000)
  ***NNAT***            205\*     8.0 (.0073)    38 (.00000)      NT                     NT             10.8 (.0053)   33 (.00000)
  ***PKIB***            464\*     7.4 (.0029)    70 (.00000)      NT                     NT             6.6 (.0013)    35 (.00000)
  ***S100A4***^**3**^   281\*     8.8 (.0012)    27 (.00000)      3.0 (.00039)           4.9 (.00000)   8.2 (.00018)   11 (.00000)
  ***TSPY1***           11\*      96 (.00002)    532 (.00000)     NT                     NT             153 (.00000)   1290 (.00000)

\*: Called \"Absent\" on all 4 control arrays; \*\*: called \"Absent\" on 3 of 4 control arrays

^1^The fold-change for either the microarray analyses or real-time RT-PCR assays (relative fold-change). P-values (Welch\'s *t*-test) are shown in parentheses.

^2^NT = not tested, because it was not significantly affected in the microarray analyses.

^3^Expression is observed in the fetal liver.

###### 

Primer sequences

  **Primers**   **Sequences**
  ------------- --------------------------
  HE1741        CCAGGGATTAGGAGTGGACC
  HE1742        GGAGGGGAAGAGCAGTTGTC
  HE2251        GATTGGACCTCATTACATAAGGG
  HE2252        TCTTTTGGGGTTAGCAAGTTG
  HE2261        AGGGTTGTGTGAAGACAGCG
  HE2262        TTGTTGCGGTGGTGGGGAAAG
  HE2245        GGACCCTCAGCCTTGTTTG
  HE2246        AACCCCCCTCACCTCATTGG
  HE2255        TGTCCAAACCAACCGCAC
  HE2256        AACAGCAACAAGCCCGTAG
  HE2253        CCTGATGTCCAGCAGAAAGTGC
  HE2254        GTTAGAAGAAGTCCTCCAAAGCG
  HE2219        TACCAGTCCAATACCATCCTGCG
  HE2220        TGCCTTCACATAGTCATCCTTGC
  HE2241        ACTGGTTGGAGTTGTGGAGACG
  HE2242        TGGAATGCTTGAAGGCTGCTC
  HE2369        AATCAAAACACCGCACCAG
  HE2370        ATCAGTGAGGGGCAAGGGGGGTTC
  HE2243        CAGACGGAACCTCAGATTTGCC
  HE2244        CAGTGCGATTTGGAAGTAACCTG
  HE2265        GCAAAGAGGGTGACAAGTTCAAGC
  HE2266        GCCAGGGTGGAAAAAAAAAAGTGC
  HE2249        CTCTGACCACAACTTCGCAG
  HE2250        CCACATTTACCCCCTCTTCC
  HE3106        CTACCCCGAGGAGAAGAAAGAG
  HE3107        CTGTGTTCAGAGAAGGAATCGTC

###### 

Real-time RT-PCR products. Positions are relative to the translational start site.

  **Gene**   **Accession_No.**            **Position**     **Primer pair**
  ---------- ---------------------------- ---------------- -----------------
  *CDK10*    [NM_003674.2](NM_003674.2)   +436 to +946     HE2261/62
  *CEBPA*    [NM_004364.2](NM_004364.2)   +1900 to +2254   HE2245/46
  *CEBPB*    [NM_005194.2](NM_005194.2)   +1216 to +1483   HE2255/56
  *CHGA*     [NM_001275](NM_001275)       +1629 to +2146   HE3106/07
  *CYP3A7*   [NM_000765.2](NM_000765.2)   +972 to +1453    HE2253/54
  *GSTP1*    [NM_000852.2](NM_000852.2)   +189 to +365     HE2219/20
  *H19*      [BC_053637](BC_053637)       +1342 to +1546   HE2241/42
  *NNAT*     [NM_005386](NM_005386)       +613 to +967     HE2369/70
  *PKIB*     [NM_181795.1](NM_181795.1)   +115 to +454     HE2243/44
  *S100A4*   [NM_002961](NM_002961)       +61 to +387      HE2265/66
  *TSPY1*    [NM_003308.2](NM_003308.2)   +782 to +1080    HE2249/50
